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Abstract
Nicastrin (NCSTN) is a component of the -secretase complex and therefore potentially a candidate risk gene for Alzheimer’s disease. Here,
we have developed a novel functional genomics methodology to express common locus haplotypes to assess functional differences. DNA
recombination was used to engineer 5 bacterial artificial chromosomes (BACs) to each express a different haplotype of the NCSTN locus. Each
NCSTN-BAC was delivered to knockout nicastrin (Ncstn/) cells and clonal NCSTN-BAC/Ncstn/ cell lines were created for functional
nalyses. We showed that all NCSTN-BAC haplotypes expressed nicastrin protein and rescued -secretase activity and amyloid beta (A)
roduction in NCSTN-BAC/Ncstn/ lines. We then showed that genetic variation at the NCSTN locus affected alternative splicing in
human postmortem brain tissue. However, there was no robust functional difference between clonal cell lines rescued by each of the 5
different haplotypes. Finally, there was no statistically significant association of NCSTN with disease risk in the 4 cohorts. We therefore
conclude that it is unlikely that common variation at the NCSTN locus is a risk factor for Alzheimer’s disease.
© 2012 Elsevier Inc.
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Alzheimer’s disease (AD) is the most common cause of
neurodegeneration. Mutations in 3 genes (amyloid precur-
sor protein [APP], presenilin 1 [PS1], and presenilin 2
[PS2]) are known to cause rare familial early onset AD
(EOAD). However, until recently the genetic factors which
influenced the common sporadic form of AD, late onset AD
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tein E (APOE) gene being for many years the only well-
replicated genetic susceptibility factor for LOAD. Recent
genome-wide association studies (GWAS) have now con-
firmed the association with the APOE 4 allele and shown
hat susceptibility to LOAD is influenced by multiple ge-
etic factors of small effect. At least 9 candidate suscepti-
ility genes for LOAD have been identified: ATP-binding
assette, sub-family A, member 7 (ABCA7), bridging inte-
rator 1 (BIN1), CD2-associated protein (CD2AP), CD33
olecule (CD33), clusterin (CLU), complement receptor 1
CR1), EPH receptor A1 (EPHA1), membrane-spanning
-domains subfamily A member 4 (MS4A4)/membrane-
panning 4-domains subfamily A member 6E (MS4A6E),
nd phosphatidylinositol binding clathrin assembly protein
PICALM) (Harold et al., 2009; Hollingworth et al., 2011;
ambert et al., 2009; Naj et al., 2011). It is predicted that
ariation in these genes, including APOE, account for ap-
roximately 32% of AD genetic risk (Fagan, 2011). How-
ver, despite the consistency achieved by recent GWAS
tudies, there has been limited success in the identification
f functional variants (Brouwers et al., 2012).
Nicastrin (NCSTN, MIM 605254) is a protein critical
o the function of the -secretase complex (Yu et al.,
000). However, evidence for a role of NCSTN in AD
usceptibility remains unclear. A recent study has shown
hat individuals carrying a rare NCSTN variant show an
ncreased risk of AD (Lupton et al., 2011). In addition,
ommon variation at the NCSTN locus may affect risk for
D. Four main haplotypes have been identified at the
CSTN locus; HapA, HapB, HapC, and HapD (Dermaut
t al., 2002). In addition, we have previously defined a
urther haplotype, HapE (Deary et al., 2005). Of these,
apB was shown to increase risk of developing familial
arly onset Alzheimer’s disease in Dutch individuals,
articularly those without an APOE 4 allele (Dermaut et
l., 2002). This was replicated in both a Sardinian (Pis-
opo et al., 2006) and Finnish study (Helisalmi et al.,
004), although the latter result was nonsignificant. How-
ver, it was not replicated in an Italian (Confaloni et al.,
003) or French study (Cousin et al., 2003). Overall, the
vidence indicates HapB may be a risk factor for AD,
hile we have shown that HapB may have an effect on
eneral cognitive ability (Deary et al., 2005).
Although the genetic data are conflicting, there is evi-
ence that protein sequence changes at the NCSTN locus
ffect protein function (Yu et al., 2000). In addition to
CSTN, the -secretase complex consists of 3 additional
ofactors: the presenilins (PS1/PS2), PS enhancer 2 (PEN2),
nd anterior pharynx defective (APH)-1. NCSTN has im-
ortant roles in the assembly and function of -secretase. It
as been implicated in the control of intracellular trafficking
f the -secretase (Spasic et al., 2007; Zhang, Y.W. et al.,
2005), which is critical to its function. The transmembrane
domain (TMD) of NCSTN is required in the interactionwith the C terminus of PS1 (Kaether et al., 2004), and the
transmembrane domain and juxtamembrane region are re-
quired in the interaction of NCSTN with APH-1 (Walker et
al., 2006). A recent molecular study identified an alterna-
tively spliced transcript of NCSTN that lacked exon 16, and
therefore lacked this juxtamembrane region. Transcripts
lacking exon 16 showed a trend for association with AD in
patients with an APOE 4 allele (Mitsuda et al., 2006).
Another important region of NCSTN is the ectodomain. A
conformational change in the NCSTN ectodomain is asso-
ciated with -secretase activity (Shirotani et al., 2003). In
addition, this domain contains a DYIGS and peptidase ho-
mologous region (DAP) domain. Although it has not re-
tained its peptidase activity (Fagan et al., 2001; Fergani et
al., 2001), this domain has retained its ability for substrate
recognition (Shah et al., 2005). Point mutations within the
DAP domain appear to augment amyloid precursor protein
(APP) processing, whereas deletions disrupt APP process-
ing, probably by preventing the exit of NCSTN from the
endoplasmic reticulum (ER) (Chen et al., 2001; Yu et al.,
2000).
Given that previous genetic studies have been incon-
clusive as to the role of NCSTN in AD susceptibility, we
have developed a novel functional genomics approach
based on the expression of different haplotypes. In this
study we have used bacterial artificial chromosome
(BAC) vectors expressing different NCSTN haplotypes to
evaluate whether haplotypic variation at the NCSTN lo-
cus contributes to functional variation. We first identified
a BAC carrying the NCSTN HapA variant and then used
serial homologous recombination to create 4 further
BACs with NCSTN HapsB–E. Subsequent analyses of
clonal cell lines expressing these haplotypes demon-
strated that all haplotypes were capable of expressing
NCSTN to restore -secretase activity and amyloid beta
(A) production to nicastrin (Ncstn/) knockout cells.
However, we were unable to demonstrate any robust
functional difference between cell lines expressing dif-
ferent haplotypes. Analysis of postmortem human brain
tissue indicated that haplotypic variation may affect
splicing of NCSTN in specific brain regions, although we
were unable to demonstrate any difference in the alter-
native splicing of NCSTN exon 16 in our cell culture
models. Finally, analysis of GWAS data from the NCSTN
locus did not reveal any statistically significant associa-
tion with disease. Overall, our thorough approach com-
bining studies in functional genomics, genetic associa-
tion, and gene expression and splicing demonstrates that
NCSTN is unlikely to be a susceptibility gene in AD.
2. Methods
2.1. Genotyping
All primers were designed using Primer3 online (Rozen
and Skaletsky, 2000) and genomic fragments were ampli-
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cedures. Genotyping was carried out by restriction digestion
and/or sequencing (Big Dye Version 3.1, Applied Biosys-
tems, Carlsbad, CA, USA).
2.2. BAC characterization
BAC clones spanning the NCSTN genomic locus were
identified using the University of California at Santa Cruz
(UCSC) genome browser (Kent et al., 2002). BACs were
obtained from Invitrogen or the BACPAC Resource Centre
(BPRC), and confirmed by exon amplification and restric-
tion digestion (Supplementary Table 1). Each BAC was
genotyped to determine the NCSTN haplotype expressed at
ach locus (Supplementary Table 2).
.3. Haplotype characterization
NCSTN haplotypes are characterized by the 4 single nucle-
tide polymorphisms (SNPs) originally described by Dermaut
t al. (2002). These SNPs may not be functional and may be
roxies for the true untyped functional variant in the haplotype
egion. To address this, we sequenced the haplotype region.
e obtained genomic DNA from individuals expressing dif-
erent NCSTN haplotypes (gifts from I. Deary and S. Harris,
niversity of Edinburgh, UK). Specifically, these individuals ex-
ressed haplotypes AD, AE, BB, and CC respectively. Disease
tatus with respect to Alzheimer’s disease was unknown. DNA
epresenting each haplotype was amplified using a forward primer
ontaining a SalI site at the 5= end (5=-TTTTTTGTCGACTC-
TATGGTGGTTCTAGGATAACT-3=) and a reverse primer
ontaining the NotI site at the 5= end (5=-TTTTTTGCGGCCGC-
CCTTTTATGTCCTTCCCAGTCA-3=). PCR amplified DNA
for each haplotype was cloned into pBluescript (pBS) and deliv-
ered to ElectroMAX DH10B cells (Invitrogen) for sequence anal-
ysis. pBS-NCSTN plasmids were sequenced in both directions
with 21 primer pairs that spanned the haplotype region (Supple-
mentary Table 3). Polymorphisms were counted as true if present
in both directions and in more than 1 clone for each haplotype.
2.4. BAC modification using Red/ET recombination
2.4.1. NCSTN
HapA BACs were modified to create NCSTN haplotypes
B, C, D, and E in a sequential manner using a 2-step
recombination protocol based on Red/ET recombination
(Muyrers et al., 2000, 2001; Zhang Y.W. et al., 2000). All
modifications were carried out in ElectroMAX DH10B
cells.
In brief, a plasmid containing RpsL-neo was linearized
and amplified using forward (5=-GGCCTGGTGATGATG-
GCGGGATC-3=) and reverse (5=-TCAGAAGAACTCGT-
CAAGAAGG-3=) primers with 5= homology arms that
matched specific genomic NCSTN DNA insertion sites
(Supplementary Table 4). Amplified products were added to
recombination-induced cells containing the Red/ET plasmid
pSC101-BAD-gbaA. The DNA fragment containing the re-
placement polymorphism was amplified from the corre- ssponding pBS-NCSTN clone (Supplementary Table 5), and
the product added to cells containing correct recombinants
from the first round. Correct recombinants were confirmed
by restriction digestion and sequencing.
2.5. BAC modification using Cre/LoxP recombination
pEHHG-NCSTN was obtained by incubating pEHHG
and NCSTN BAC with Cre enzyme (Merck, Darmstadt,
Germany).
2.6. Tissue culture
Three mouse embryonic fibroblast cell lines, Ncstn wild
type (Ncstn/), Ncstn heterozygotes (Ncstn/) and Ncstn
knockout (Ncstn/) (gifts from P. Wong, Johns Hopkins
niversity School of Medicine, USA), were cultured in Dul-
ecco’s modified Eagle’s medium (DMEM) (Invitrogen,
rand Island, NY, USA) supplemented with 10% fetal bovine
erum (FBS), P/S, and L-Glut. pEHHG-NCSTN stable clones
ere generated by transfecting pEHHG-NCSTN into Ncstn/
cells using Lipofectamine 2000 (Invitrogen). Transfected cells
were diluted after 48–72 hours in medium containing 225
g/mL hygromycin (Invitrogen) and single colonies isolated
after 10–15 days. All cells were cultured at 37 °C in 5%
(vol/vol) CO2.
2.7. RT-PCR
RNA was prepared using TRIzol (Invitrogen). RNA was
resuspended in diethylpyrocarbonate (DEPC) water. cDNA
was made from 2 g RNA using the first Strand cDNA
Synthesis Kit for RT-PCR (AMV, Roche, West Sussex, UK).
Human-specific primers amplified exon 9 to exon 11; forward
(5=-CAGCTCGAGGATGGTCTACG-3=), reverse (5=-GAG-
AGGCTGGGACTGATTG-3=), product 250 base pair (bp).
2.8. Western blot analysis
Protein was prepared using lysis buffer (50 mM Tris
pH 8, 150 mM NaCl, 1% Triton X200, protease inhibi-
tor). Protein was reduced with -mercaptoethanol or di-
hiothreitol (DTT) and 5–10 g was resolved on either a
0% sodium dodecyl sulfate polyacrylamide gel electro-
horesis (SDS-PAGE) gel (Invitrogen) or an 8% SDS-
AGE gel (Pierce). Following transfer to a positively
harged nylon membrane, Hybond N (GE Healthcare,
uckinghamshire, UK), protein samples were incubated
ith antibody; anti-nicastrin (1:1000) (Sigma-Aldrich,
orset, UK), anti--actin (1:10,000) (Abcam, Cam-
bridge, UK), polyclonal rabbit anti-mouse horseradish
peroxidase (HRP) (1:5000) (Dako, Glostrup, Denmark),
and polyclonal goat anti-rabbit (1:4000) (Dako). Samples
were visualized using ECL plus (GE Healthcare) or Su-
perSignal West Dura Extended Duration Substrate
(Thermo, Fisher Scientific, Rockford, IL, USA). Each
protein sample was analyzed in triplicate. -actin expres-
ion was used to normalize for equal loading between
amples. Total protein from Ncstn/ cells was used to
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GeneSnap (Syngene, Cambridgeshire, UK).
2.9. Copy number determination
NCSTN transgene copy number of each clonal cell line was
determined using human-specific quantitative real-time PCR
(RT-PCR). Primers were designed within intron 2 (IN2) of
NCSTN and 2 control primer sets targeting mouse sequences
were used: D3MIT12 and D14MIT5 (Supplementary Table 6).
A positive control construct for each primer set was generated
by the amplification of human and mouse genomic DNA with
the NCSTN IN2 and D3MIT12 and D14MIT5 primer pairs
respectively. Amplified products were cloned into pCR2.1-
TOPO (Invitrogen), introduced into DH5 cells (One Shot
AX Efficiency, Invitrogen) and confirmed by sequence anal-
sis. For real-time detection a MyiQ Single-Color Real-Time
CR machine (Bio-Rad, Hertfordshire, UK) was used using a
tandard PCR program with amplification at 65 °C and data
ollection at 72 °C (NCSTN IN2, D14MIT5), or amplification
t 68 °C with data collection at 78 °C (D3MIT5). Plasmid
NA was titrated and amplified with the DyNAmo Flash
YBR Green qPCR kit (NEB, Ipswich, MA, USA), using 0.25
M (NCSTN IN2, D14MIT5) or 1-M primer (D3MIT12)
rimer. All reactions had an efficiency of 90%–110%. A stan-
ard curve for each primer pair was generated by plotting the
og of the copy number (x-axis) versus CT values (y-axis).
To determine the copy number of each NCSTN clone,
genomic DNA was amplified in separate reactions with all
3 primer pairs. Specifically, 10 ng genomic DNA was am-
plified using optimized conditions and each reaction was set
up in triplicate. Experimental CT values were converted to
og copy number values using the appropriate standard
urve and absolute copy number for each clonal cell line
as determined by normalization to the average value ob-
ained from D3MIT12 and D14MIT5.
.10. Notch activity assay
Cells were seeded in a 24-well plate at a density of
 105 in media with no antibiotics. Cells were trans-
ected with 444-ng firefly luciferase Notch-CBF-1 re-
orter, 4xwtCBF-1-luc (a gift from Dr. G. Weinmaster,
CLA Medical School, USA) and 500 ng of the S2
leaved form of human Notch-1, EN1 (a gift from Dr.
. Aster, Brigham and Women’s Hospital, USA) using
ipofectamine 2000. To control for transfection effi-
iency, 54 ng phTKRenilla luciferase (Promega, Madi-
on, WI, USA) was used. Empty vector (pcDNA3.1) was
ncluded where necessary to maintain constant DNA con-
entrations. A constitutively active luciferase plasmid,
GL4.13 (Promega), was used as a between plates con-
rol. Transfected samples were analyzed for firefly and
enilla luciferase activities after 24 hours using the Dual-
lo Luciferase Assay System (Promega) and measured
sing a Synergy 2 luminescence Microplate Reader (Bio-
ek, Winooski, VT, USA). All values were normalized toells containing reagent but no cells. Data were obtained
rom 3 independent experiments of 6 repeats.
.11. A enzyme-linked immunosorbent assay (ELISA)
Cells were seeded in a 24-well plate at a density of
.5  105 in media containing no hygromycin. Cells were
ransfected with 250 ng of a hAPPswe plasmid (Mudher et
l., 2001) and 250 ng -galactosidase (Promega) using
Lipofectamine 2000 (Invitrogen). Media was removed 4
hours posttransfection media and 250-L fresh media
dded. Conditioned media was removed after 20 hours
nd cleared by centrifugation. Supernatant for A40 as-
says was diluted 1:2 using dilution buffer containing 1
mM AEBSF, while supernatant for A42 assays was used
eat with 1 mM AEBSF. Supernatants were stored at
20 °C until measured. Cell lysates were prepared and
ssayed for -galactosidase expression using the -gal-
actoside Enzyme Assay System (Promega). Secreted
A40 and A42 levels were determined using colorimetric
ELISA kits (A40, Invitrogen; A42, Millipore, Billerica,
MA, USA). Data were obtained from 3 independent ex-
periments of 6 repeats. A values were normalized using
-galactosidase results.
.12. Expression of alternative transcripts from
ostmortem brain tissue
Brain tissue was obtained from healthy control individ-
als from 3 UK brain banks; the Oxford Project to Inves-
igate Ageing and Memory (OPTIMA), the MRC London
rain Bank for Neurodegenerative Diseases and the South
est Dementia Brain Bank (SWDBB). RNA was extracted
rom brain tissue using Trizol and an RNase Easy Column
Qiagen, West Sussex, UK). cDNA was made as before.
Expression levels of NCSTN transcripts containing and
lacking exon 16 were determined using quantitative RT-PCR.
Primers were designed that uniquely amplified transcripts that
contained exon 16 (full length transcript, FL Tc, forward:
5=-AGTGAAAACAAGGATCTGTATGAGT-3=, reverse: 5=-
AGGGTGATCAACTCAAGCTC-3=) or lacked exon 16
Ex16, forward: 5=-CAAGGATTTGATCACCCTGA-3=, re-
erse: 5=-GCTGGGGTCCTCCTCAGTAT-3=). Three human
ousekeeping genes (PGBD, GNB2L1, ABL1) were selected
rom an initial panel of 10 (Zhang, X. et al., 2005). For
eal-time detection a MyiQ Single-Color Real-Time PCR ma-
hine (Bio-Rad) was used. cDNA was amplified using 0.5–
-M primer with the DyNAmo Flash SYBR Green qPCR kit
(NEB) and using a standard PCR program with amplification
at 68 °C and data collection at 78 °C. Each cDNA sample was
amplified in triplicate with all primer pairs. Experimental CT
values for each sample were compared and sample represent-
ing CT minimum for each primer pair was identified. The
equation where raw data  1  ECtmin–Ct was used to deter-
mine relative expression levels for each sample (Livak
and Schmittgen, 2001; Pfaffl, 2001). Raw values obtained
for FL Tc and Ex16 were normalized using the geomean
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were calculated for each data point to incorporate age and
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cell lines
cDNA was made from clonal cell lines as previously
described. Expression levels of NCSTN transcripts contain-
ng and lacking exon 16 were determined using quantitative
eal-time PCR (RT-PCR) as described in 2.12. Two mouse
ousekeeping genes (RPL6 and OAZ1) were selected from
n initial panel of 5 (de Jonge et al., 2007).
.14. Analysis of NCSTN genotype data
AD case and control genotype data were obtained
rom 4 consortia; the Genetic and Environmental Risk for
lzheimer’s disease (GERAD1) Consortium (Harold et
l., 2009) (Supplementary Fig. 1), the Translational
enomics Research Institute (TGen) (Corneveaux et al.,
010) (Supplementary Fig. 2), the European Alzheimer
isease Initiative (EADI) (Lambert et al., 2009) (Sup-
lementary Fig. 3), and the Mayo (MAYO) Clinic (Car-
asquillo et al., 2009) (Supplementary Fig. 4) (Supple-
entary Table 7).
Power calculations were carried out using CaTS (Skol
t al., 2006). All calculations were carried out with a
isease prevalence of 0.3 and a type I error rate of 0.01.
irectly genotyped and imputed data were available for
6 NCSTN SNPs (Supplementary Table 8). Four SNPs,
s2274185, rs6664438, rs6677637, and rs17370539,
verlap with haplotype SNPs identified in our sequence
nalysis. Statistical analysis was carried out using PLINK
1.07 (Purcell et al., 2007). SNPs were examined for
ssociation with disease singly or by specified haplotype
nalysis. Two stratified data sets, with or without the
POE 4 allele, were analyzed similarly. METAL, a tool
or the meta-analysis of genome-wide association scans,
as used to analyze the combined SNP and haplotype
ata from the 4 cognitive studies (Willer et al., 2010). A
ignificance threshold of p  0.05 was applied to the
eta-analysis.
. Results
.1. BAC characterization
The genomic locus of NCSTN is 15.7 kb in length. We
Table 1
The 5 nicastrin (NCSTN) haplotypes differ at up to 14 locations
rs12240253 rs12239747 rs2274185
Hap A C A C
Hap B T G C
Hap C C A G
Hap D C A C
Hap E C G C
Location Intron 5 Exon 6 Intron 6
equence analysis of the 7 kb haplotype (Hap) region identified 14 SNPs t
o tag each haplotype are marked in bold and underlined.dentified 16 BACs that contained the NCSTN gene and 1ach was genotyped at 4 SNP locations (rs12239747,
s2274185, rs7528638, rs17370539). All BACs contai-
ed the most common haplotype, HapA. One BAC,
TC635J11, was selected for all further experiments (Fig.
A). CTC635J11 is approximately 121.1 kb in size and
arried by the vector pBeloBAC11. In addition to NCSTN,
TC635J11 carries the full length Nescient helix loop helix
(NHLM1) and Vang-like 2 (VANGL2) genes. NHLM1
elongs to a putative family of transcription factors and
ANGL2 is involved in planar cell polarity. It also contains
he 5= end of the coatomer protein complex, subunit alpha
COPA) gene.
.2. Haplotype characterization
The original SNPs representing the haplotype may not
hemselves be functional and may be proxies for the true
ntyped functional variant in the haplotype region. The
CSTN haplotype spans a genomic region of approximately
000 bp (Dermaut et al., 2002). To identify unknown po-
ential functional variants, we obtained DNA from 4 indi-
iduals expressing different NCSTN haplotypes (S. Harris
nd I. Deary, University of Edinburgh). These were sub-
loned into pBS. Two pBS-NCSTN clones per haplotype
ere sequenced across a 7638-bp region. Sequence results
onfirmed the 4 original SNPs and identified an additional
0 SNPs that differed between the haplotypes (Table 1, Fig.
A). HapC and HapE were most similar to HapA and
iffered at 1 SNP position each (rs2274185, HapC;
s12239747, HapE). HapD was found to differ at 6 SNP
ositions (rs1041066, rs78110462, rs6427515, rs45503695,
s17370539, rs41266887). HapB was most dissimilar to
apA, differing at 8 SNP positions (rs12240253,
s12239747, rs6664438, rs6664627, IVS8316G¡A,
s7528638, rs6677637, rs17370539). Two of the 14 SNPs
ere located in exons (rs12239747, rs6664627), but are
ynonymous changes not expected to affect amino acid
equence.
We compared the sequencing results to information de-
osited in dbSNP (National Centre for Biotechnology In-
ormation) and the 1000 Genomes Project (1000 Genomes
roject Consortium, 2010). On comparison with dbSNP,
ur study has identified 13 of the 26 SNPs located in the
aplotype region, plus 1 novel SNP. Compared with the
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were either very rare or were heterozygous between indi-
viduals with the same haplotype, suggesting they were not
haplotype-specific SNPs.
3.3. BAC modification
Sequential rounds of Red/ET recombination, using a
positive/negative selection strategy, were used to introduce
each polymorphism identified in our sequencing analysis to
the HapA BAC, CTC635J11, to generate an additional 4
vectors; BAC-NCSTN HapB, HapC, HapD, and HapE. Fol-
lowing these modifications, BAC-NCSTN Haps A–E were
further modified by the addition of pEHHG (Fig. 1B). Suc-
cessful addition of pEHHG by cre-LoxP recombination was
confirmed by pulse field gel electrophoresis (Fig. 1C).
3.4. Characterization of clonal cell lines
The successful delivery of pEHHG-NCSTN Haps A–E to
Ncstn/ cells was visualized by the expression of green
uorescent protein (GFP) (Fig. 2A). Thirty-five clonal cell
ines were initially established; 6 for HapA, 8 for HapB,
for HapC, 6 for HapD, and 8 for HapE. Subsequently,
ach clonal cell line was characterized to confirm expres-
ion of NCSTN at both the RNA and protein level. cDNA
as amplified using human-specific primers that ampli-
ed a 250 bp DNA fragment spanning exon 9 to exon 11.
he NCSTN antibody used here binds to the N-terminal
nd binds both immature, nonfully glycosylated, NC-
TN, approximately 110 kDa (immature nicastrin [iNC-
TN]) and mature, fully glycosylated, NCSTN, approx-
mately 130 kDa (mature nicastrin [mNCSTN]). Of the
5 cell lines originally picked, 32 were shown to express
orrectly spliced mRNA (Fig. 2B) and protein (Fig. 2C).
ach NCSTN haplotype returned the level of total NC-
TN (Fig. 2D), mNCSTN (Fig. 2E), and the ratio of
NCSTN:mNCSTN (Fig. 2F) to broadly the same level
bserved in wild type Ncstn cells.
NCSTN cell lines were analyzed for copy number. Absolute
opy number was determined by normalizing to the average copy
umber of 2 diploid mouse control genes (D3MIT12, D14MIT5).
he majority of clones had fewer than 10 copies of NCSTN,
owever 4 had 50 to 60 copies. Twelve clonal cell lines with a
Table 1
(continued)
rs7528638 rs78110462 rs6677637 rs64
C G C C
G G T C
C G C C
C A C T
C G C C
Intron 10 Intron 11 Intron 11 Intrimilar NCSTN copy number and comparable protein expression tere selected for functional analyses; 2 HapA clones, 2 HapB
lones, 1 HapC clone, 4 HapD clones, and 3 HapE clones.
.5. Functional analysis of NCSTN clones
Twelve clonal cell lines were used to evaluate the ability
f each NCSTN haplotype to rescue -secretase function
nd A production in the Ncstn/ cells.
First, we compared -secretase activity by assessing
luciferase levels from a Notch reporter gene assay trans-
fected into each cell line (Fig. 3A). Membrane bound
Notch is processed by functional -secretase generating
n intracellular fragment that activates gene transcrip-
ion. We show here that each NCSTN haplotype restored
-secretase activity toward the level observed in wild
ype Ncstn cells (Fig. 3A). There was no correlation
etween -secretase activity (Fig. 3A) and the expression
level of mNCSTN (Fig. 2E).
Next, to determine the ability of each NCSTN haplo-
type to restore A production to Ncstn/ cells, we
quantified levels of secreted A40 and A42 in each cell
ine following transfection of the hAPPswe plasmid.
Again, we showed that levels of secreted A40 (Fig. 3B)
nd secreted A42 (Fig. 3C) are above levels observed in
cstn/ cells. Notably, the ratio of secreted A42 to
A40 (A42:A40) was broadly similar to the ratio ob-
erved in wild type Ncstn cells (Fig. 3D).
.6. Expression analysis of NCSTN in postmortem human
rain samples
To evaluate the existence of tissue-specific haplotype-
elated splicing variation, we carried out expression analysis
f postmortem brain tissue (Fig. 4D). Twenty-seven indi-
iduals were genotyped and brain tissue was obtained from
hose expressing specific NCSTN: HapAA (n  8), HapAB
n  10), and HapAC (n  9). Frontal cortex, entorhinal
ortex, and hippocampus was obtained where available
Table 2).
Our results show that not only is there variation in the
atio of FL Tc:Ex16 transcripts in different brain re-
ions from the same individual, but that there is also
ariation between individuals with the same NCSTN hap-
otype. Analysis of the haplotype combined data showed
rs455036955 rs17370539 rs41266887
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ortex from individuals with HapAA compared with
hose with HapAB (p  0.05 and p  0.01) (Fig. 4B).
ithin individuals carrying HapAA, we observed that
here was a highly significantly increased level of FL Tc
n the entorhinal cortex compared with frontal cortex and
ippocampus (both p  0.05) (Fig. 4A). Additionally,
within individuals carrying HapAB, we observed a nom-
inally significant increase in FL Tc in the hippocampus
ompared with frontal cortex (p  0.001) and entorhinal
ortex (p  0.05) (Fig. 4A).
.7. Expression analysis of NCSTN in clonal cell lines
An alternatively spliced NCSTN variant, lacking exon
6, has been reported. To determine whether haplotype-
pecific sequence variation affects splicing we quantified
xpression levels of each transcript in each clonal cell line
sing RT-PCR. We determined the expression level of full
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Fig. 2. Characterization of Ncstn/ cell lines expressing nicastrin (NCSTN
CSTN RNA; and (C) NCSTN protein; pictures representative. Quantitative
cell lines have restored: (D) total NCSTN levels (sum of immature nicas
iNCSTN:mNCSTN ratio. Haplotype results are the average of results obtai
ype (WT), n  3; and KO, n  3. Error bars are the mean  standard dength NCSTN transcript (FL Tc) and transcript lacking exon w16 (Ex16) from each sample (Fig. 4D) and found there
was no statistically significant difference between haplo-
types (p  0.18) (Fig. 4C).
3.8. Genetic analysis of NCSTN genotype data
To evaluate genetic variation at the NCSTN locus for
association with AD, we have analyzed genotype data from
16 SNPs in 4 cohorts. Power calculations show that this
study had 100% power to detect effect sizes of odds ratio
(OR) 1.2 and greater with a minor allele frequency of at
least 0.05 (data not shown).
No individual SNP was associated with disease risk in
the overall or APOE stratified sample in our meta-analysis
t p  0.05 (Supplementary Table 9).
Four SNPs, rs2274185, rs6664438, rs6677637, and
s17370539, overlapped with SNPs that were engineered as
art of the haplotype (Fig. 1A); genotype data for these SNPs
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stratified sample in our meta-analysis at p 0.05 (Supplemen-
tary Table 10). Indeed, haplotype analyses indicate that SNP
rs17370539 is not a haplotype tagging SNP as originally re-
ported; HapA is the most common haplotype and was reported
to be tagged by the major allele of rs17370539 (G), however
the most common haplotype in the TGen cohort at this loci
expresses the minor allele of rs17370539 (A).
4. Discussion
NCSTN is a critical component of the -secretase com-
plex and there is some previous evidence to suggest that it
is a genetic risk factor for Alzheimer’s disease. In this study,
we undertook a novel functional genomics approach to
investigate the functional impact of common haplotypic
variation on NCSTN function and also sought to replicate
revious genetic findings in a large meta-analysis.
Through sequencing analysis we have determined that
he putative NCSTN risk haplotype, HapB, was most differ-
nt from the common haplotype, HapA: differing at 8 SNPs
hroughout the haplotype region. HapD differed at 6 SNPs,
hile HapC and HapE were most similar to HapA, differing
t 1 SNP each. However, we cannot exclude the effect of
ery rare variants, which may contribute to disease. The
CSTN haplotype region spans a number of functional
omains; the DAP domain is coded by NCSTN exons 7–13
and is likely to be important in substrate recognition, while
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Fig. 3. Functional rescue of -secretase activity in Ncstn/ cells by nicast
bility to process Notch, compared with knockout (KO) cells. Haplotype
 18; D, n  72; E, n  54; wild type (WT), n  12; and KO, n  18. C
40, (C) A42, and (D) secreted A42:A40, compared with KO cells. H
, n  33, 30, 30; C, all n  12; D, all n  46; E, all n  10; WT, n 
bbreviation: mNCSTN, mature nicastrin.the transmembrane region of NCSTN is required in theinteraction with the C terminus of PS1. The SNPs that we
identified in our sequencing analysis either lie outside cod-
ing sequences or do not change the amino acids encoded.
Here we tested the hypothesis that noncoding genetic vari-
ation in the NCSTN locus could affect NCSTN function in
other ways, for example by regulating expression or splic-
ing.
Our data are the first example of the functional analyses
of NCSTN haplotypic variation. We have demonstrated that
that all 5 NCSTN haplotypes restore -secretase activity and
 production to an Ncstn/ cell line and that Notch
ctivity and secreted levels of A42:A40 are broadly sim-
ilar across all 5 haplotypes. Overall, we were not able to
detect any robust functional differences between the haplo-
types. Furthermore, we did not detect any statistically sig-
nificant genetic association of NCSTN polymorphisms with
disease risk in the meta-analysis of 4 large consortia, how-
ever, again, this does not exclude a functional role for rare
variation.
However, we do demonstrate a significant difference in
NCSTN splicing from postmortem brain tissue of a small
number of healthy individuals expressing different haplo-
types, indicating a potential effect on neuronal-specific
splicing. Here, we show that there was a highly significantly
increase in full length NCSTN transcript expressed from
HapAA individuals than from HapAB individuals in ento-
rhinal cortex and frontal cortex tissue. Further, within
HapAA individuals the level of full length transcript in
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cortex. Alternatively spliced exon 16 encodes residues im-
portant in stabilizing the interaction of NCSTN and APH-1
(Walker et al., 2006). This result suggested that there could
be an increased association of NCSTN with APH-1 in the
entorhinal cortex of HapAA individuals. Due to the com-
petitive binding of APH-1 and Rer1p to NCSTN, one may
hypothesize that NCSTN molecules lacking exon 16 are
likely to remain in the early endosomal compartments and
not participate in a functional -secretase complex. HapA is
he most common haplotype of NCSTN (f  0.8), which
ay indicate a positive selection pressure; however, this
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Fig. 4. Alternative splicing of nicastrin (NCSTN) exon 16. Quantitative re
individuals. Brain regions denoted: frontal cortex (FC), hippocampus (Hip)
of standardized scores was generated for each haplotype and brain region f
lines expressing each haplotype. (D) Transcripts were amplified using exo
containing exon 16 (FL Tc) over transcripts lacking exon 16 (Ex16). Sig
genomic DNA.
Table 2
Brain tissue samples were collected from individuals expressing
different haplotypes of nicastrin (NCSTN)
FC EC Hip
A/A 8 5 8
A/B 10 8 2
A/C 9 9 5
Tissue samples were collected, where possible, from the frontal cortexp(FC), entorhinal cortex (EC), and hippocampus (Hip) regions.tudy was very small and replication is required in a larger
ample. We did not detect any differences in the alternative
plicing of exon 16 in our clonal cell lines, although this
ould be due to inherent differences in the in vivo tissue
nalyses and in vitro cell culture work. Further, it was
ecessary to use a mouse Ncstn/ knockout cell line so as
to be able assay NCSTN transgene function in this study and
we cannot exclude any species-specific effects on NCSTN
splicing; nor can we exclude the potential effect of trans-
factors that may have haplotype-specific effects.
The functional effect of noncoding variants, particularly
for a late-onset disease, is likely to be very subtle and may
be tissue-specific. Here, we demonstrate that splicing dif-
ferences are specific to only certain regions of the brain,
emphasizing the difficulty in modeling this effect in vitro.
4.1. Conclusions
The NCSTN gene has been implicated as a risk factor for
D in numerous genetic studies. In addition, there is evi-
ence to indicate that genetic variation at this locus may
ffect function. To clarify the role of NCSTN polymor-
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postmortem tissue, and genetic association. Using clonal
cell lines, we were able to functionally rescue an Ncstn/
cell line with 5 haplotypes of NCSTN; however, the function
of each NCSTN haplotype was broadly similar and we did
not detect any robust haplotype-specific functional differ-
ences. Further, we detected no difference in splicing be-
tween clonal cell lines expressing different haplotypes. In
addition, we did not detect any statistically significant ge-
netic association of NCSTN polymorphisms with disease
risk. Our study is limited to the common variants that we
have identified; and we cannot exclude the contribution of
additional rare variants that we have not been able to eval-
uate. However, in postmortem brain tissue, we show that
genetic variation at the NCSTN locus may participate in the
tissue-specific control of alternative splicing. The possibil-
ity remains that genetic variation at the NCSTN locus may
affect disease risk by influencing splicing control, however,
we believe that taken together, our results conclude that
NCSTN is probably not a risk factor for Alzheimer’s dis-
ease. This is the first time that the functional importance of
genomic variation to Alzheimer’s disease has been assessed
in this way.
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